DPP IV Inhibitors

DPP IV Inhibitors

  • April 2016 •
  • 192 pages •
  • Report ID: 3846707 •
  • Format: PDF
This report analyzes the worldwide markets for DPP IV Inhibitors in US$ Million. The Global market is analyzed by the following Drugs: Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors. The US market is analysed in terms of sales and number of prescriptions, by the following Drug Segments: Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 23 companies including many key and niche players such as -

AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck & Co, Inc.
Mitsubishi Tanabe Pharma Corporation